Unbound liver concentration is the true inhibitor concentration that determines cytochrome P450-mediated drug–drug interactions in rat liver

References

• Bertz RJ, Granneman GR. (1997). Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 32:210–58
   PubMed Web of Science ®Google Scholar
• Brown HS, Galetin A, Hallifax D, Houston JB. (2006). Prediction of in vivo drug-drug interactions from in vitro data: factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4. Clin Pharmacokinet 45:1035–50
   PubMed Web of Science ®Google Scholar
• Chovan JP, Ring SC, Yu E, Baldino JP. (2007). Cytochrome P450 probe substrate metabolism kinetics in Sprague–Dawley rats. Xenobiotica 37:459–73
   PubMed Web of Science ®Google Scholar
• Chu X, Korzekwa K, Elsby R, et al. (2013). Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver. Clin Pharmacol Ther 94:126–41
   PubMed Web of Science ®Google Scholar
• DIDB: Copyright University of Washington 1999–2016. UW Metabolism and Transport Drug Interaction Database [Internet]. Available from: https://www.druginteractioninfo.org/ [last accessed 28 Dec 2014]
   Google Scholar
• Einolf HJ. (2007). Comparison of different approaches to predict metabolic drug-drug interactions. Xenobiotica 37:1257–94
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA): Guideline on the investigation of drug interactions. 2012 [Internet]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf [last accessed 21 Jun 2012]
   Google Scholar
• Greenblatt DJ, Zhao Y, Venkatakrishnan K, et al. (2011). Mechanism of cytochrome P450-3A inhibition by ketoconazole. J Pharm Pharmacol 63:214–21
   PubMed Web of Science ®Google Scholar
• Guengerich FP, Martin MV, Beaune PH, et al. (1986). Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 261:5051–60
   PubMed Web of Science ®Google Scholar
• Huang SM, Strong JM, Zhang L, et al. (2008). New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol 48:662–70
   PubMed Web of Science ®Google Scholar
• Ito K, Brown HS, Houston JB. (2004). Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol 57:473–86
   PubMed Web of Science ®Google Scholar
• Ito K, Iwatsubo T, Kanamitsu S, et al. (1998a). Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Annu Rev Pharmacol Toxicol 38:461–99
   PubMed Web of Science ®Google Scholar
• Ito K, Iwatsubo T, Kanamitsu S, et al. (1998b). Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 50:387–412
   PubMed Web of Science ®Google Scholar
• Kishimoto W, Takano J, Senda C, et al. (2000). Quantitative prediction of in vivo drug interactions between nevirapine and antifungal agents from in vitro data in rats. Biol Pharm Bull 23:1027–32
   PubMed Web of Science ®Google Scholar
• Kondo S, Sugimoto I. (1987). Moment analysis of intravenous, intraduodenal, buccal, rectal and percutaneous nifedipine in rats. J Pharmacobio-dyn 10:462–9
   PubMedGoogle Scholar
• Kosugi Y, Hirabayashi H, Igari T, et al. (2012). Evaluation of cytochrome P450-mediated drug-drug interactions based on the strategies recommended by regulatory authorities. Xenobiotica 42:127–38
   PubMed Web of Science ®Google Scholar
• Kumar S, Kwei GY, Poon GK, et al. (2003). Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: role of CYP3A and P-glycoprotein. J Pharmacol Exp Ther 304:1161–71
   PubMed Web of Science ®Google Scholar
• McGinnity DF, Tucker J, Trigg S, Riley RJ. (2005). Prediction of CYP2C9-mediated drug-drug interactions: a comparison using data from recombinant enzymes and human hepatocytes. Drug Metab Dispos 33:1700–7
   PubMed Web of Science ®Google Scholar
• Niwa T, Shiraga T, Takagi A. (2005). Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull 28:1805–8
   PubMed Web of Science ®Google Scholar
• Obach RS, Walsky RL, Venkatakrishnan K, et al. (2006). The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316:336–48
   PubMed Web of Science ®Google Scholar
• Perdaems N, Blasco H, Vinson C, et al. (2010). Predictions of metabolic drug-drug interactions using physiologically based modelling: two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil. Clin Pharmacokinet 49:239–58
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T, Chu X, Gibson C, et al. (2013). Drug-drug interaction studies: regulatory guidance and an industry perspective. AAPS J 15:629–45
   PubMed Web of Science ®Google Scholar
• Rioux N, Bellavance E, Bourg S, et al. (2013). Assessment of CYP3A-mediated drug-drug interaction potential for victim drugs using an in vivo rat model. Biopharm Drug Dispos 34:396–401
   PubMed Web of Science ®Google Scholar
• Scherling D, Karl W, Radtke M, et al. (1992). Biotransformation of nifedipine in rat and dog. Arzneimittelforschung 42:1292–300
   PubMed Web of Science ®Google Scholar
• Shibata N, Gao W, Okamoto H, et al. (2002). Drug interactions between HIV protease inhibitors based on physiologically-based pharmacokinetic model. J Pharm Sci 91:680–9
   PubMed Web of Science ®Google Scholar
• Smith DA, DI L, Kerns EH. (2010). The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat Rev Drug Discov 9:929–39
   PubMed Web of Science ®Google Scholar
• Takedomi S, Matsuo H, Yamano K, et al. (1998). Quantitative prediction of the interaction of midazolam and histamine H2 receptor antagonists in rats. Drug Metab Dispos 26:318–23
   PubMed Web of Science ®Google Scholar
• Tucker GT. (1992). The rational selection of drug interaction studies: implications of recent advances in drug metabolism. Int J Clin Pharmacol Ther Toxicol 30:550–3
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration (FDA): Guidance for industry: drug interaction studies—study design, data analysis, implications for dosing, and labeling recommendations. 2012 [Internet]. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm292362.pdf [last accessed 1 Mar 2012]
   Google Scholar
• Uchida S, Tanaka S, Namiki N. (2014). Simultaneous and comprehensive in vivo analysis of cytochrome P450 activity by using a cocktail approach in rats. Biopharm Drug Dispos 35:228–36
   PubMed Web of Science ®Google Scholar
• Yabe Y, Galetin A, Houston JB. (2011). Kinetic characterization of rat hepatic uptake of 16 actively transported drugs. Drug Metab Dispos 39:1808–14
   PubMed Web of Science ®Google Scholar
• Yamano K, Yamamoto K, Kotaki H, et al. (1999). Quantitative prediction of metabolic inhibition of midazolam by itraconazole and ketoconazole in rats: implication of concentrative uptake of inhibitors into liver. Drug Metab Dispos 27:395–402
   PubMed Web of Science ®Google Scholar
• Yamano K, Yamamoto K, Kotaki H, et al. (2000). Quantitative prediction of metabolic inhibition of midazolam by erythromycin, diltiazem, and verapamil in rats: implication of concentrative uptake of inhibitors into liver. J Pharmacol Exp Ther 292:1118–26
   PubMed Web of Science ®Google Scholar
• Yamaoka K, Tanigawara Y, Nakagawa T, Uno T. (1981). A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobio-dyn 4:879–85
   PubMedGoogle Scholar
• Yeo KR, Jamei M, Rostami-Hodjegan A. (2013). Predicting drug-drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach. Expert Rev Clin Pharmacol 6:143–57
   PubMed Web of Science ®Google Scholar
• Zhou S, Yung Chan S, Cher Goh B, et al. (2005). Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 44:279–304
   PubMed Web of Science ®Google Scholar